# Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder

> **NCT03434366** · PHASE2 · SUSPENDED · sponsor: **Guangzhou Women and Children's Medical Center** · enrollment: 50 (estimated)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** ketamine and dexmedetomidine
- **DRUG:** ketamine
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT03434366
- **Lead sponsor:** Guangzhou Women and Children's Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2018-01-20
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 50 (ESTIMATED)
- **Why stopped:** The effects are not good
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03434366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03434366, "Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03434366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*